# Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

> **NCT02286843** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Breast Cancer Metastases
- HER2 Positive Breast

## Interventions

- **RADIATION:** 89Zr-trastuzumab
- **DEVICE:** PET/CT scan
- **RADIATION:** 89Zr-pertuzumab

## Key facts

- **NCT ID:** NCT02286843
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-06
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02286843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02286843, "Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02286843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*